At the 18th International Conference on Illegal Diseases, Professor Li Xinli shared relevant basic and clinical research, and deeply interpreted the key mechanisms and role basis of Qili Qiangxin Capsule to improve the prognosis of heart failure patients.
heart failure treatment is mainly divided into drug treatment and surgical treatment. In terms of surgical treatment, the commonly used methods in clinical practice include cardiac resynchronization treatment, buried cardioversion defibrillator defibrillator treatment, coronary artery bypass grafting , etc.
However, the use of these drugs has certain limitations without exception. Regarding the current status of drug treatment for heart failure, Professor Li Xinli said: "We hope to master the indications of the drug, use all the drugs that should be used, and try to titrate to the target dose."
According to data from the China Heart Failure Center, the current prevalence of heart failure in my country is 1.3%, which estimates that there are about 13.7 million heart failure patients in my country. After continuous verification by traditional Chinese medicine evidence-based medical research, traditional Chinese medicine has played an increasingly important role in the prevention and treatment of heart failure.
, led by Academician Gao Runlin, , Academician Zhang Boli, and Professor Huang Jun, the "Research on the Efficacy and Safety Evaluation of Qifeng Qiangxin Capsule in the Treatment of Chronic Heart Failure" launched in 2011. The first Affiliated Hospital of Nanjing Medical University, where Professor Li Xinli is located, participated in it and undertakes a lot of important work.
" Professor Li Xinli concluded: "This study has been recognized by international scholars, allowing everyone to see that Chinese medicine and Western medicine can work together and bring benefits to patients with heart failure.
Western medical theory believes that the basic principles of heart failure treatment are "strengthening the heart, diuresis, and diffusion of blood vessels". The concept of traditional Chinese medicine meridian theory is highly similar to that of Western medicine. It points out that heart failure is mainly caused by deficiency of qi and yang, and the treatment method is "invigorating qi and temperature yang, promoting diuresis and reducing swelling, promoting blood circulation and unblocking meridians". It can be seen that although Chinese and Western medicine describe differently, the principles are the same.
After a series of basic and evidence-based research exploration, the role of Qifeng Qiangxin Capsule "invigorates qi, temperatures, yang, promotes diuresis and reduces swelling, and promotes blood circulation and unblocks the meridians" has been confirmed, but which of the ingredients have truly played a therapeutic effect? Why is the addition of Qifeng Qiangxin Capsule on the basis of standard Western medicine treatment better than Western medicine alone? To solve these questions, Professor Li Xinli's team conducted a research on Qifeng Qiangxin Prescription.
It is reported that the "Questein-Kungxin Capsule Treatment of Complex Endpoint Events in Chronic Heart Failure (QUEST Research)" conducted by Professor Li Xinli's team is a sub-topic of the National Key R&D Program Project "Research on the Intervention of Cardiovascular Events Chain of the Biology Theory Guidance System". It aims to evaluate the effectiveness and safety of Qiweiqiang Capsule with two hard endpoints, "mortality rate" and "rehospitalization rate due to heart failure" through modern evidence-based medical evidence.
This research has been recognized by many international scholars in its design. In November 2018, Professor Adler from Harvard Medical School went to the First Affiliated Hospital of Nanjing Medical University to listen to the QUEST research report and discussed it; in July 2020, Professor MarcA. Phafer from Harvard Medical School affirmed the design of the program and progress of the QUEST research plan and progress, and looked forward to the release of the research results. Professor Li Xinli also expressed his sincere expectations for the impact of
on the future study of this hard endpoint study. He said that cardiovascular experts from the American Academy of Sciences have proposed four-part plots of drug development, namely "clinical, mechanism, evidence-based, and guidelines". Qili Qiangxin Capsules have undergone clinical efficacy tests, and there are also a series of mechanisms and evidence-based studies. After the QUEST study was released blindly, if the results meet expectations, Qili Qiangxin Capsules can be included in it, and the "new four links" will be upgraded to "new five links".
Professor Li Xinli presented a number of original research results at the meeting, confirming that the formula and pathogenesis of Qili Qiangxin Capsule for the treatment of chronic heart failure are consistent with the pathogenic mechanism of Western medicine. "I am very honored that I have published many papers related to Qifeng Qiangxin Capsules in my life." Professor Li Xinli sighed.
Professor Li Xinli summarized in the meeting: "We must do the evidence-based research on traditional Chinese medicine more meticulously, and we will work together to promote our research results to the world.Because the motherland's medicine is inherited from Chinese culture, if you want to introduce traditional Chinese medicine theory to foreign experts, you must constantly communicate and communicate, and comprehensively display and interpret the prescriptions and mechanisms of representative traditional Chinese medicine such as Qili Qiangxin Capsules. ”
